HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GlaxoSmithKline derma acquisitions

This article was originally published in The Rose Sheet

Executive Summary

Consumer Healthcare division acquires five Rx dermatology products from Elan Pharmaceuticals to complement existing OTC portfolio, which includes Oxy acne products and Abreva cold sore medication, GlaxoSmithKline says. Pharmaceutical additions include Aclovate, Cutivate and Temovate, primarily recommended to stop itching, swelling and redness associated with skin conditions, Oxistat, an anti-fungal medication, and Emgel, an anti-acne treatment. Five products generated sales of $35 mil. in first six months of 2002 and revenues of $62 mil. in 2001, according to firm. Elan Pharmaceuticals is exiting the dermatology business...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS010858

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel